Wnt family member 1Genealiases: BMND16 · INT1 · OI15
Q-omics provides the consensus-scored WNT1 profile across patient tissues and cancer cell-line models. WNT1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, WNT1 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, WNT1 RNA expression shows 15,353 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight SKCM, KIRC, and DLBC as cancer lineages where WNT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WNT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WNT1 survival associations across molecular data types. WNT1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WNT1 RNA expression–survival associations across cancer types. High WNT1 expression shows unfavorable associations in UVM, but favorable associations in SKCM, HNSC, SCLC, LIHC and CESC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for WNT1 RNA expression.
This table summarizes WNT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for WNT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WNT1 shows lower tumor expression in BRCA, CHOL, LUSC and READ and higher tumor expression in KIRC and KIRP. The KIRC box plot shows higher WNT1 RNA expression in tumor versus normal tissue (log2 FC = +0.131, t-test p < 0.001).
This table shows molecular features associated with WNT1 in patient tissues and cancer cell lines. In patient samples, WNT1 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, WNT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
